Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Arons Website

Evgeny Arons, Ph.D.

Selected Publications

1)  Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Nat. Genet. 46: 8-10, 2014.
[Journal]
2)  Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin. Cancer Res. 19: 6873-81, 2013.
[Journal]
3)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
[Journal]
4)  Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ.
Evidence of canonical somatic hypermutation in hairy cell leukemia.
Blood. 117: 4844-51, 2011.
[Journal]
5)  Arons E, Kreitman RJ.
Molecular variant of hairy cell leukemia with poor prognosis.
Leuk. Lymphoma. 52 Suppl 2: 99-102, 2011.
[Journal]
6)  Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB.
Response of hairy cell leukemia to bendamustine.
Leukemia & lymphoma. 2011.
[Journal]
7)  Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ.
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Blood. 114: 4687-95, 2009.
[Journal]
8)  Arons E, Suntum T, Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ.
PRAME expression in hairy cell leukemia.
Leuk. Res. 32: 1400-6, 2008.
[Journal]
9)  Arons E, Suntum T, Sunshine J, Stetler-Stevenson M, Kreitman RJ.
Immunoglobulin light chain repertoire in hairy cell leukemia.
Leuk. Res. 31: 1231-6, 2007.
[Journal]
10)  Arons E, Sorbara L, Raffeld M, Stetler-Stevenson M, Steinberg SM, Liewehr DJ, Pastan I, Kreitman RJ.
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Cancer Immunol. Immunother. 55: 1100-10, 2006.
[Journal]
11)  Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
Clin. Cancer Res. 12: 2804-11, 2006.
[Journal]
12)  Arons E, Sunshine J, Suntum T, Kreitman RJ.
Somatic hypermutation and VH gene usage in hairy cell leukaemia.
Br. J. Haematol. 133: 504-12, 2006.
[Journal]
13)  Arons E, Kunin V, Schechter C, Ehrlich R.
Organization and functional analysis of the mouse transporter associated with antigen processing 2 promoter.
J. Immunol. 166: 3942-51, 2001.
[Journal]
14)  Arons E, Zusman T, Ran M.
The in vivo enhancement of IL-1alpha receptor expression on polyoma virus transformed tumor derived cells.
Int. J. Oncol. 12: 1379-83, 1998.
[Journal]
15)  Zusman T, Lisansky E, Arons E, Anavi R, Bonnerot C, Sautes C, Fridman WH, Witz IP, Ran M.
Contribution of the intracellular domain of murine Fc-gamma receptor type IIB1 to its tumor-enhancing potential.
Int. J. Cancer. 68: 219-27, 1996.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 3/10/2014.